NCI-H1975 Transfection

* This product is for research use only. Not intended for use in the treatment or diagnosis of disease.

Non-small cell lung cancer (NSCLC), which accounts for approximately 85 % of lung cancers, is one of the most common cancers globally, leading to cancer-related death. NCI-H1975 cell, also known as H1975 and NCIH1975 cell, is a cell line established in July 1988 from a woman with no smoking history. NCI-H1975 cells are epithelial-like in morphology and have the characteristics of adherent growth. NCI-H1975 have been used in analytical studies of new drugs for lung cancer.

BOC Sciences offers reagents specifically formulated and optimized for the transfection of NCI-H1975 cells.

Product Information

Catalog Number BT-000048
ContentsNCI-H1975 Transfection Kit includes NCI-H1975 transfection reagent and transfection enhancer.
StorageStore at 4℃. If stored properly, the reagent is stable for up to 6 months.
ShippingThe NCI-H1975 transfection reagent is supplied in liquid form and is transported at ambient temperature.
Transfection EfficiencyAt least 90 % efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Use LimitationsFor research use only.

Features

  • Unique formulation-maximizes transfection performance of NCI-H1975 cells.
  • Invisible cytotoxicity.
  • Effective and robust cell delivery.
  • High efficiency for small RNA (siRNA, shRNA, miRNA), mRNA, pDNA transfection.
  • Reagents showed at least 90% transfection efficiency for siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Optimization of transfection

  • The highest transfection efficiency is obtained by varying the density of NCI-H1975 cells and the amount of transfection reagent.
  • The high passage rate of NCI-H1975 cells and the use of antibiotics (or growth factors) may require a larger volume of NCI-H1975 transfection reagent in each reaction.

Reference

  1. Tang ZH; et al. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line. Oncotarget. 2016: 7(49): 81598-81610.

Related Sections: